List of Namenda Xr drug patents

Namenda Xr is owned by Allergan.

Namenda Xr contains Memantine Hydrochloride.

Namenda Xr has a total of 2 drug patents out of which 0 drug patents have expired.

Namenda Xr was authorised for market use on 21 June, 2010.

Namenda Xr is available in capsule, extended release;oral dosage forms.

Namenda Xr can be used as treatment of moderate to severe dementia of the alzheimer's type.

The generics of Namenda Xr are possible to be released after 24 September, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(6 years from now)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 June, 2010

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMENDA XR before it's patent expiration?
More Information on Dosage

NAMENDA XR family patents

11

United States

1

Brazil

1

Australia

1

Canada

1

Mexico

1

EA

1

China

1

Japan

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in